# Tasly Pharmaceutical

> Tasly Pharmaceutical is a VC fund in Tianjin backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tianjin, China
- Total investments: 6
- Last investment: Aug 2026
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/tasly-pharmaceuticals/about/
- X (Twitter): https://twitter.com/taslyint
- Website: https://www.taslyint.com
- Facebook: https://www.facebook.com/taslyint

Tasly Pharmaceutical is a VC fund in Tianjin focused on Health Care and Biotechnology. Tasly is pioneering the most aggressive paradigm shift in modern medicine: scientifically proving that the 5,000-year old medical practice of Modern Traditional Chinese Medicine (mTCM) – healing the body with pure, natural herbs, is as effective as treating it with chemical and synthetic drug compounds. This will fulfill an unmet clinical need forhealthcare providers and patients alike by being able to treat serious diseases with chemical-free products, which could be a game changer in modern medicine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Wellness | 1 | 17% |
| Mobile Apps | 1 | 17% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 50% |
| Series B | 1 | 17% |
| Post-IPO Equity | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 3 | 50% |
| France | 1 | 17% |
| United States | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hopstem | Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering. | $29.6M | Series C | Aug 10, 2026 |  |
| Mauna Kea Technologies | Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval for a wide range of applications in the UnitedStates and more than 40 countries around the World. |  | Post-IPO Equity | May 31, 2023 |  |
| Zhangshang Tangyi | Zhangshang Tangyi is a health management platform with a focus on diabetes. It allows patients to upload their own health data to their mobile app and receive treatment guidance from doctors. Zhangshang Tangyi was founded in 2014 and is based in Hangzhou, Zhejiang. | $100M | Series C | Jan 07, 2019 |  |
| I-Mab Biopharma | I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. . | $220M | Series C | Jun 29, 2018 |  |
| I-Mab Biopharma | I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. . | $220M | Series C | Jun 29, 2018 |  |
| Ascletis | Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China'scapital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases. | $35M | Series B | Sep 02, 2015 |  |

6 of 6 investments shown.

## Co-investors
- [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group) — VC Fund, 2 deals together
- [C-Bridge Capital](https://shizune.co/investors/profile/c-bridge-capital) — VC Fund, 2 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 2 deals together
- [Hillhouse Investment](https://shizune.co/investors/profile/hillhouse-capital) — VC Fund, 2 deals together
- [Hony Capital](https://shizune.co/investors/profile/hony-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Tasly Pharmaceutical invest in?

Tasly Pharmaceutical invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 6 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tasly Pharmaceutical last invest?

The most recent investment recorded for Tasly Pharmaceutical closed in Aug 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co